279 related articles for article (PubMed ID: 35799305)
1. A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.
Saburi A; Kahrizi MS; Naghsh N; Etemadi H; İlhan A; Adili A; Ghoreishizadeh S; Tamjidifar R; Akbari M; Ercan G
J Ovarian Res; 2022 Jul; 15(1):81. PubMed ID: 35799305
[TBL] [Abstract][Full Text] [Related]
2. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract][Full Text] [Related]
3. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.
Moghbeli M
J Ovarian Res; 2021 Sep; 14(1):127. PubMed ID: 34593006
[TBL] [Abstract][Full Text] [Related]
5. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
[TBL] [Abstract][Full Text] [Related]
6. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
7. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
[TBL] [Abstract][Full Text] [Related]
8. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
9. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
10. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
11. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
13. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.
Boyerinas B; Park SM; Murmann AE; Gwin K; Montag AG; Zillhardt M; Hua YJ; Lengyel E; Peter ME
Int J Cancer; 2012 Apr; 130(8):1787-97. PubMed ID: 21618519
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study.
Lou E; Vogel RI; Hoostal S; Wong P; Grad A; Monu M; Łukaszewski T; Deshpande J; Dickson EL; Klein M; Linden MA; Subramanian S; Teoh D; Geller MA
Oncologist; 2019 Nov; 24(11):1422-e1013. PubMed ID: 31346130
[TBL] [Abstract][Full Text] [Related]
15. The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer.
Alharbi M; Zuñiga F; Elfeky O; Guanzon D; Lai A; Rice GE; Perrin L; Hooper J; Salomon C
Endocr Relat Cancer; 2018 Dec; 25(12):R663-R685. PubMed ID: 30400025
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
17. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
18. Identification of exosomal and non‑exosomal microRNAs associated with the drug resistance of ovarian cancer.
Feng Y; Hang W; Sang Z; Li S; Xu W; Miao Y; Xi X; Huang Q
Mol Med Rep; 2019 May; 19(5):3376-3392. PubMed ID: 30864705
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-mediated drug resistance in ovarian cancer.
Mihanfar A; Fattahi A; Nejabati HR
J Cell Physiol; 2019 Apr; 234(4):3180-3191. PubMed ID: 28628227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
